Manufacturers report positive results for umbralisib and ublituximab for chronic lymphocytic leukaemia in UNITY-CLL trial

This this phase III study, this combination of ublituximab (3rd generation anti-CD20 monoclonal antibody) and umbralisib (PI3K delta inhibitor) had a statistically significant improvement in PFS vs obinutuzumab + chlorambucil at interim analysis. The trial will be stopped early.


Biospace Inc.